Article 1
The Annex to Regulation (EC) No 2380/2001 is replaced by the Annex to this Regulation.
Commission Implementing Regulation (EU) No 406/2011 of 27 April 2011 amending Regulation (EC) No 2380/2001 as regards the composition of the feed additive maduramicin ammonium alpha Text with EEA relevance
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
The Annex to Regulation (EC) No 2380/2001 is replaced by the Annex to this Regulation.
Premixtures and compound feed containing maduramicin ammonium alpha produced in accordance with Regulation (EC) No 2380/2001 may continue to be placed on the market and used until the existing stocks are exhausted.
This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union.
ANNEX ‘ANNEX Identification number of the additive Name of the holder of authorisation Additive (Trade name) Composition, chemical formula, description, analytical method Species or category of animal Maximum age Minimum content Maximum content Other provisions End of period of authorisation mg of active substance/kg of complete feedingstuff with a moisture content of 12 % Coccidiostats and other medicinal substances E 770 Alpharma Belgium BVBA Maduramicin ammonium alpha 1 g/100 g (Cygro 1 %) Additive composition Maduramicin ammonium alpha: 1 g/100 g Carboxymethylcellulose sodium: 2 g/100 g Calcium sulphate dihydrate: 97 g/100 g Active substance Maduramicin ammonium α C 47 H 83 O 17 N CAS number: 84878-61-5, ammonium salt of a polyether monocarboxylic acid produced by a fermentation process by the strain Actinomadura yumaensis (ATCC 31585) (NRRL 12515) Related impurities: Maduramicin ammonium β: < 10 % Turkeys 16 weeks 5 5 1. Use prohibited at least 5 days before slaughter. 2. Indicate in the instructions for use: ‘Dangerous for equines’. ‘This feedingstuff contains an ionophore: simultaneous use with certain medicinal substances (e.g. tiamulin) can be contraindicated’. 15.12.2011’
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.